Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win

 
• By Kevin Grogan

Following the failure late last year of Regeneron's combination of Eylea with nesvacumab, a Phase II success for the Swiss major's RG7716 is a boost for the theory that a VEGF/Ang-2 combo therapy can transform the treatment of certain eye diseases.

Eye chart
How low can you go? RG7716 improved visual acuity compared to Lucentis • Source: Shutterstock

More from Sensory

More from Therapy Areas